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Abstract
Introduction—There are limited data on acute HIV infection (AHI) prevalence during pregnancy.
Methods—Malawian pregnant women admitted in the third trimester and meeting eligibility criteria
underwent dual HIV rapid antibody testing. AHI prevalence was retrospectively detected through
HIV RNA pooling of seronegative plasma.
Results—Among 3825 pregnant women screened, dual HIV rapid testing indicated that 30.2%
were HIV positive, 69.7% were HIV negative and 0.1% were indeterminate. Sensitivity and
specificity of dual rapid testing was 99.0% and 98.7%, respectively. Of 2666 seronegative specimens,
2327 had samples available for HIV RNA pooling; 5 women (0.21%) (95% CI: 0.03, 0.40%) had
AHI with a median peripartum viral load of 1,324,766 copies/mL.
Discussion—Pregnant women are at risk for AHI, warranting counseling of all women and their
sexual partners about incident HIV during pregnancy. Dual HIV rapid tests have high sensitivity and
specificity. HIV testing should be repeated in the third trimester and/or at delivery.
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In the absence of antiretroviral therapy (ART) or prophylaxis, the risk of HIV transmission
from mother to child is approximately 15-20% in Europe, 15-30% in the United States (US)
and 25-35% in Africa (The Working Group on MTCT of HIV, 1995, Volmink et al., 2007).
Although these transmission rates have improved with the introduction of antiretroviral therapy
for the prevention of mother to child transmission (PMTCT), only a minority of women receive
PMTCT (WHO, 2008). The Joint United Nations Programme on HIV/AIDS (UNAIDS)
estimates that the percent of HIV positive Malawian pregnant women and their infants who
received ART for PMTCT increased from 5% in 2005 to 26% in 2007
(http://data.unaids.org/pub/Report/2008/malawi_2008_country_progress_report_en.pdf).
Accordingly, HIV-attributable mortality rates in sub-Saharan Africa for children under the age
of five have exceeded 30 per 1000 (Volmink et al., 2007). Since the greatest risk of mother to
child transmission (MTCT) occurs during the intrapartum period (Mock et al., 1999),
understanding associated factors which are amenable to intervention remains crucial.
Maternal plasma HIV RNA level is a strong independent risk factor for MTCT (John and
Kreiss, 1996, John et al., 2001, Khouri et al., 1995). In the study by John and colleagues, HIV
transmission risk was 9% for women with viral loads <10,000 copies/mL compared with 45%
among women with viral loads above the median of 43,000 copies/mL; women with viral loads
above the median had a four-fold higher risk of transmission (95% confidence interval (CI),
2.2-7.2). Accordingly, since the highest viral burden in blood and genital secretions is detected
during the ramp-up phase of viremia in acute HIV infection (AHI) (Pilcher et al., 2001), AHI
during pregnancy may carry a high risk of MTCT HIV transmission. In one study, HIV
shedding into cervicovaginal fluid reached levels observed in chronically infected patients
within 3 to 5 weeks of symptoms consistent with acute retroviral syndrome (Pilcher et al.,
2001). Further, in another study each one log increase in mean HIV-1 DNA titer in
cervicovaginal secretions was associated with a higher risk of vertical transmission (odds ratio
(OR), 2.28; 95% CI, 1.09-4.78; p = .03) (Tuomala et al., 2003).
Few studies have evaluated the incidence of AHI among pregnant women, particularly in areas
of high HIV prevalence such as Malawi, as the detection of AHI requires additional testing to
detect HIV RNA or p24 antigen in antibody negative subjects. However, most resource poor
settings utilize only rapid HIV testing for HIV diagnosis as recommended by the World Health
Organization (WHO) (WHO, 2001) given the test advantages of low cost and rapid results
while requiring no instrumentation, refrigeration or electricity, with just minimal training. In
addition, there is considerable evidence that the sensitivity and specificity of HIV rapid tests
are comparable to or better than 3rd generation enzyme immunoassays for the detection of HIV
antibodies, particularly when used in combination as with dual rapid testing algorithms (Aidoo
et al., 2001, WHO, 2004, Arthur et al., 2005, Branson, 2000).
HIV sero-incidence in sub-Saharan Africa among pregnant women has ranged from 1.3 per
100 persons years to 5.2 per 100 person years during pregnancy through the post-partum period
(Mbizvo et al., 2001, Gray et al., 2005, Rehle et al., 2007, Lu et al., 2009). Further, in high risk
populations, such as STD clinics in sub-Saharan Africa, a substantial number of subjects with
AHI have been detected (Pilcher et al., 2004). In order to provide needed data on HIV infection
and AHI prevalence in the sub-Saharan African PMTCT setting, we present findings from a
cross-sectional study on the prevalence of AHI in pregnant women in Malawi.
Materials and Methods
From December 2000 to June 2004, 3825 pregnant women were enrolled into a cohort study
at Queen Elizabeth Central Hospital (QECH), the main tertiary referral hospital in southern
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Malawi (Mwapasa et al., 2004). More detailed methods for recruitment and enrollment of
participants in the cohort study are described elsewhere (Mwapasa et al., 2004). Pregnant
women admitted to the QECH antenatal ward before the onset of active labor who met
eligibility criteria and provided informed consent were enrolled. All participants received HIV
pre-test counseling followed by blood collection for HIV and hemoglobin testing.
HIV status was determined by dual testing defined as the use of two simultaneous HIV rapid
tests, Determine HIV-1/2 Rapid Test (Abbott Laboratories, Illinois, USA) and the SeroCard
HIV-1/2 Rapid Test (Trinity Biotech, Co Wicklow, Eire), or Determine and HIVSPOT
HIV-1/2 Rapid Test (Genelabs Diagnostics, Singapore). Discordant results were resolved with
a third, alternative rapid test on a subsequent sample. Post-test HIV counseling was performed
and demographic and medical information, as well as maternal and infant morbidity data were
documented using standardized questionnaires. HIV-infected women and their infants received
nevirapine according to the HIVNET 012 protocol.
For the current analysis, 2327 anonymized, available stored specimens from participants with
negative HIV rapid testing results were evaluated for AHI at the University of North Carolina
at Chapel Hill labs. Individual antibody-negative specimens were manually pooled with a
pyramid-type 2 stage pooling algorithm, using an initial 10:1 pooling of 100ul aliquots from
each specimen, followed by a second 5:1 pooling of aliquots from each 10-specimen pool to
yield a master pool containing sample from 50 individuals. Master pools were screened for
HIV RNA using the ultrasensitive Roche RNA assay with a lower limit of sensitivity of 50
copies/mL. Only 10-specimen pools from reactive master pools and individual specimens from
reactive 10-specimen pools underwent further HIV RNA testing. Specimens from the master
pool with detectable HIV RNA underwent individual testing for viral load with the Roche
Monitor assay, version 1.5 (Branchberg, NJ) with a lower detection limit of 400 copies/mL.
All HIV RNA positive specimens were tested for HIV antibodies by Western Blot (Genetic
Systems HIV-1 Western Blot. Bio-Rad, Hercules, CA) on stored plasma. AHI was defined as
negative or indeterminate rapid HIV test results, a negative or indeterminate Western Blot, and
a positive HIV RNA test. Participants with AHI were tested for herpes simplex virus type 2
(HSV-2) using the FDA-approved HerpeSelect® gG-2 ELISA (Focus Diagnostics, Cypress,
CA) at the UNC Laboratory.
Data were entered into Microsoft Access and analyzed in STATA, version 8.2 (StataCorp,
College Station, Texas). The database for the parent study (Mwapasa et al., 2004) was stripped
of all personal identifiers. Prevalence of established HIV and AHI were determined. The study
was approved by the Malawi College of Medicine Research and Ethics Committee and the
institutional review board at the University of North Carolina at Chapel Hill.
Results
3825 pregnant Malawian women were enrolled and screened for HIV. Median age of
participants was 22 years of age (IQR: 19-26). The majority or 3467 (90.6%) were married,
3023 (79.0%) were unemployed, and 1401 (36.6%) of participants were primigravid. HIV
status was determined with two different rapid tests (dual testing), and indicated that 1155
(30.2%) of women were HIV positive, 4 were indeterminate (because only one rapid test was
performed), and 2666 (69.7%) were HIV negative. Notably, of the 1155 HIV positive pregnant
women, only 66 (5.7%) reported a previous diagnosis of HIV despite report of prenatal care
in all but 5 (0.43%) of women.
A consecutive sample using 583 (50.5%) specimens from the 1155 rapid test positive women
were retrospectively tested for HIV RNA. Of these, 553 (94.9%) were HIV RNA positive, and
30 (5.1%) were HIV RNA negative. Western blot testing was performed on the 30 rapid test
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positive but HIV RNA negative samples, and revealed that 6 were western blot negative, 5
were indeterminate and 19 were positive; reflecting 11 false positive results by rapid testing
(see Figure 1) if Western blot testing is considered the gold standard.
Of the 2666 antibody negative pregnant women, 2327 (87.3%) enrollment samples were
available for additional HIV testing for AHI. Eleven subjects who were negative on dual rapid
testing had detectable HIV RNA on pooling. Western blot testing for these 11 subjects revealed
that six had established HIV infection, indicating false negative rapid test results. The median
VL for these participants was 83,759 copies/mL (IQR: 10,816 – 124,360). Of the remaining
2321 seronegative pregnant women, 5 (0.21%) (95% CI: 0.03, 0.40%) had detectable plasma
HIV RNA suggesting AHI. Overall, the sensitivity of dual rapid testing to detect HIV was
99.0% and specificity was 98.7%, with HIV RNA testing considered the gold standard. A
similar result was found when additional Western blot results were used to assess test
performance indicating a sensitivity of 99.1% and specificity of 99.5%, respectively (see Figure
2).
Among the five acutely infected pregnant women, median age was 20 years (range 17-35).
Four of five (80.0%) acutely infected women were married, 3 (60.0%) were primigravids, only
one had no formal education, and none were employed. Three of the five (60.0%) pregnant
women with AHI were positive for HSV-2, but none had a history of tuberculosis, a prior STD
or active syphilis. One subject with AHI was diagnosed with malaria at the time of study
enrollment. One participant with AHI at enrollment reported a fever in the week preceding
delivery, and 4 reported headache and generalized body pain in the same period. Three of five
women with AHI had a viral load of greater than 1 million copies/mL (range 283,340 copies/
mL to 17,627,630 copies/mL). Other than the very high levels of HIV RNA among these 3
women with AHI, there were no other clear baseline characteristics which distinguished cases
of AHI compared with the remainder of the cohort.
As expected the median viral load for the subjects with AHI was very high at 1,324,766 copies/
mL (IQR: 385,875 - 6,887,916), compared with a median VL of 35,537 copies/mL (IQR: 9958
- 109,779) for 589 women with established HIV infection on whom HIV RNA results were
available. The median estimated gestational age at the time of study enrollment and the date
of detection of acute HIV infection was 36 weeks (range 31 – 44). No data from infants born
to mothers with AHI is available.
Discussion
There have been a very limited number of studies of incident HIV infection in pregnant women
(Mbizvo et al., 2001, Gray et al., 2005, Lu et al., 2009), and only one prior attempt to identify
the subset of women with acute infection in the US (Patterson et al., 2007). Although the
prevalence of AHI (0.21%) in this study population of pregnant Malawian women was low,
this study likely underestimates the true AHI prevalence in this high HIV prevalence population
since most women underwent HIV testing only in their third trimester. Thus, AHI (associated
with very high viral loads) was likely missed at an earlier time point during pregnancy among
many women in this high prevalence population. As might be expected, AHI was four times
higher in Malawi than in a study of seronegative pregnant women in the US (Patterson et al.,
2007). The risk of HIV during pregnancy reflects unprotected intercourse among couples which
is likely the norm. In addition, hormonal changes associated with pregnancy may increase
susceptibility to HIV infection (Brabin, 2002). A variety of other risk factors have been shown
to increase HIV acquisition, particularly HSV-2 infection (Wald and Link, 2002), regardless
of whether individuals are symptomatic; three out of five women with AHI in this study had
chronic HSV-2 infection.
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Maternal-fetal transmission of HIV has been independently associated with higher HIV viral
load (John et al., 2001) and genital tract DNA (John et al., 2001), as well as genital ulcer disease
(GUD) (John et al., 2001). Prior work in this cohort also revealed that CCR5 polymorphisms
(Tkachuk et al., 2001), maternal-fetal microtransfusions (Kwiek et al., 2006, Kwiek et al.,
2008) and syphilis (Mwapasa et al., 2006) were risk factors for MTCT. Maternal viral load has
been shown to increase the risk of both in utero and intrapartum transmission (Mock et al.,
1999). Since the highest viral loads in the blood and the genital tract are observed during the
first few weeks of HIV infection (Pilcher et al., 2001), concern for in utero and intrapartum
transmission of HIV during this phase seems well justified. A single prospective study reported
no difference in vertical transmission between women who seroconverted during pregnancy
and those who tested positive at their initial antenatal visit (Roongpisuthipong et al., 2001).
However, in the latter study median viral loads were similar in the two groups at delivery
(17,505 and 20,845 copies/ml, respectively; p = .80), suggesting that few women were acutely
infected near the peripartum period, when risk is highest. In contrast, the high median viral
load of 1,324,766 copies/mL among women with AHI in the third trimester in this study might
be anticipated to increase the risk for HIV transmission. However, the infants born to women
with AHI in this study were not available for study.
Dual rapid testing performed better for HIV screening in this study than recently reported in a
Ugandan trial, which reported a sensitivity of 97.7% and a specificity of 94.1% (Gray et al.,
2007). Combining all test results available we observed a sensitivity range of 99.0 to 99.1%
and a specificity range of 98.7 to 99.5% for the detection of HIV, including AHI. Our findings
indicate that the simultaneous use of dual rapid tests was effective in detecting HIV infection.
However, 11 HIV infected women with AHI or false negative rapid tests were not detected
and could not benefit from antiretroviral therapy to prevent HIV MTCT.
There are a number of limitations to our study. First, the retrospective laboratory methods of
AHI detection limited our ability to provide information on infants of AHI patients and HIV-
infected women in the study. The lack of outcome data for infants limits drawing any
conclusions on the clinical significance of testing and providing PMTCT to pregnant women
with AHI. Second, this study was conducted in an area of high HIV prevalence, possibly
limiting the applicability of these data to other study populations. Third, the use of two
seronegative tests as part of the AHI definition will fail to detect seropositive individuals with
early HIV infection who are also likely to have high HIV RNA levels, and are likely at increased
risk for vertical transmission. The narrow window of seronegativity for AHI with current rapid
tests may partially explain the discrepancy between rapid tests and western blot results
demonstrated in Figure 1.
This is the first time cross sectional screening for AHI has been applied to pregnant women in
sub-Saharan Africa. However, our data are consistent with several studies in which additional
HIV cases were detected by testing for HIV virus in seronegative subjects (Pilcher et al.,
2004). This approach has the potential advantage of allowing the “real-time” detection of
subjects and the immediate provision of treatment and prevention interventions. However,
given the small number of cases detected and the lack of proof of benefit(s) to mothers and
infants, such screening in this setting remains experimental. However, it is clear that pregnant
women and their spouses (both HIV positive and negative) need counseling about safer sex
and the risk and dangers of acquiring HIV during pregnancy. In addition, our data support
guidelines which recommend repeat antibody HIV testing at delivery despite prior negative
results (Branson et al., 2006, Lu et al., 2009).
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HIV testing results from screening and retrospective detection of acute HIV infection.
†Only one rapid test performed.
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HIV testing results applied to sensitivity and specificity calculations with viral load versus
western blot as the gold standard.
aNot all samples underwent Western blot testing, precluding use of Western blot as the gold
standard in sensitivity and specificity calculation.
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